EA201491046A1 - TRANSMUKOSAL'S DEVICES FOR DELIVERY OF MEDICINES FOR USE IN THE RELIEF OF CHRONIC PAIN - Google Patents

TRANSMUKOSAL'S DEVICES FOR DELIVERY OF MEDICINES FOR USE IN THE RELIEF OF CHRONIC PAIN

Info

Publication number
EA201491046A1
EA201491046A1 EA201491046A EA201491046A EA201491046A1 EA 201491046 A1 EA201491046 A1 EA 201491046A1 EA 201491046 A EA201491046 A EA 201491046A EA 201491046 A EA201491046 A EA 201491046A EA 201491046 A1 EA201491046 A1 EA 201491046A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chronic pain
devices
transmukosal
medicines
relief
Prior art date
Application number
EA201491046A
Other languages
Russian (ru)
Other versions
EA034529B1 (en
Inventor
Эндрю Финн
Нирадж Васишт
Original Assignee
Байоделивери Сайенсиз Интернэшнл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоделивери Сайенсиз Интернэшнл, Инк. filed Critical Байоделивери Сайенсиз Интернэшнл, Инк.
Publication of EA201491046A1 publication Critical patent/EA201491046A1/en
Publication of EA034529B1 publication Critical patent/EA034529B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем документе предложены способы лечения хронической боли путем введения низких доз бупренорфина два раза в сутки (или один раз в сутки) с помощью трансмукозального устройства для доставки лекарств. Указанные способы и устройства обеспечивают эффективное лечение хронической боли без значительных побочных эффектов.The present document provides methods for treating chronic pain by administering low doses of buprenorphine twice a day (or once a day) using a transmucosal drug delivery device. These methods and devices provide effective treatment for chronic pain without significant side effects.

EA201491046A 2011-12-21 2012-12-21 Method of treating chronic pain in an opioid experienced subject using a transmucosal drug delivery device EA034529B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
PCT/US2012/071330 WO2013096811A2 (en) 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief

Publications (2)

Publication Number Publication Date
EA201491046A1 true EA201491046A1 (en) 2014-11-28
EA034529B1 EA034529B1 (en) 2020-02-18

Family

ID=48669710

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992762A EA201992762A1 (en) 2011-12-21 2012-12-21 TRANSMUCOSAL DEVICES FOR THE DELIVERY OF MEDICINES FOR USE IN THE RELIEF OF CHRONIC PAIN
EA201491046A EA034529B1 (en) 2011-12-21 2012-12-21 Method of treating chronic pain in an opioid experienced subject using a transmucosal drug delivery device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201992762A EA201992762A1 (en) 2011-12-21 2012-12-21 TRANSMUCOSAL DEVICES FOR THE DELIVERY OF MEDICINES FOR USE IN THE RELIEF OF CHRONIC PAIN

Country Status (16)

Country Link
EP (1) EP2793870A4 (en)
JP (1) JP6255349B2 (en)
KR (4) KR20190110628A (en)
CN (2) CN104125828A (en)
AU (4) AU2012358308A1 (en)
BR (1) BR112014015329A2 (en)
CA (1) CA2859859A1 (en)
EA (2) EA201992762A1 (en)
HK (1) HK1203365A1 (en)
IL (2) IL233075A0 (en)
IN (1) IN2014DN06117A (en)
MX (2) MX362217B (en)
SG (3) SG10202012743WA (en)
UA (1) UA118540C2 (en)
WO (1) WO2013096811A2 (en)
ZA (1) ZA201804381B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (en) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flat drug preparation for application and release of buprenorphine or a pharmacologically comparable substance in the oral cavity and process for its preparation
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (en) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flat pharmaceutical preparation for transmucosal administration of oxycodone or a comparable active ingredient in the oral cavity, for use in pain therapy and addiction therapy
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
JP4292570B2 (en) 2001-04-27 2009-07-08 味の素株式会社 N-substituted pyrazole-O-glycoside derivatives and therapeutic agents for diabetes containing them
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (en) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Procedures for a combination drug treatment, as well as suitable drug combinations
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1968539A2 (en) 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
JP2009533187A (en) 2006-04-12 2009-09-17 スパイナルモーション， インコーポレイテッド Posterior spine apparatus and method
RS54764B1 (en) 2006-07-21 2016-10-31 Biodelivery Sciences Int Inc Transmucosal delivery devices with enhanced uptake
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN105833420A (en) * 2008-06-23 2016-08-10 生物递送科学国际公司 Multidirectional mucosal delivery devices and methods of use
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
CN104125828A (en) 2014-10-29
SG10201710667YA (en) 2018-02-27
KR102026321B1 (en) 2019-09-27
IN2014DN06117A (en) 2015-08-14
EP2793870A4 (en) 2016-02-17
ZA201804381B (en) 2022-12-21
BR112014015329A8 (en) 2017-06-13
IL285091A (en) 2021-08-31
CN110123792A (en) 2019-08-16
MX362217B (en) 2019-01-09
UA118540C2 (en) 2019-02-11
MX2021012154A (en) 2021-11-03
JP6255349B2 (en) 2017-12-27
EP2793870A2 (en) 2014-10-29
IL233075A0 (en) 2014-07-31
AU2021202042A1 (en) 2021-04-29
WO2013096811A2 (en) 2013-06-27
EA034529B1 (en) 2020-02-18
SG10202012743WA (en) 2021-01-28
JP2015500886A (en) 2015-01-08
AU2012358308A1 (en) 2014-07-24
WO2013096811A3 (en) 2014-07-24
MX2014007350A (en) 2014-09-15
HK1203365A1 (en) 2015-10-30
KR20190110628A (en) 2019-09-30
EA201992762A1 (en) 2020-07-31
KR20210003313A (en) 2021-01-11
SG11201403075XA (en) 2014-07-30
CA2859859A1 (en) 2013-06-27
KR20140106720A (en) 2014-09-03
BR112014015329A2 (en) 2017-06-13
AU2017258916A1 (en) 2017-11-30
KR20220047889A (en) 2022-04-19
AU2017258916B2 (en) 2019-01-17
AU2019202602A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MX2020004023A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
CY1116727T1 (en) Multiple Sclerosis Treatment With LAQUINIMOD
IN2015DN00450A (en)
EA201691155A1 (en) COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES
EA201590655A8 (en) COMBINATION OF LACHINIMODE AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MX342001B (en) Treatment of lupus arthritis using laquinimod.
MX352824B (en) USE OF LEVOCETIRIZINE and MONTELUKAST IN THE TREATMENT OF INFLUENZA, COMMON COLD and INFLAMMATION.
MX2015012322A (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders.
MX2017006938A (en) Combination therapy for treatment of cancer.
EA201270071A1 (en) A METHOD OF TREATING A PATIENT NEEDING ASPIRIN TREATMENT
AR093182A1 (en) METHOD TO TREAT OVERWEIGHT OR OBESITY
MX2015012315A (en) Use of levocetirizine and montelukast in the treatment of traumatic injury.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015011775A (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis.
MX2015010296A (en) Treatment of multiple sclerosis with laquinimod.
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
MX2015016418A (en) Dihydroetorphine for the provision of pain relief and anaesthesia.
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
TW201642906A (en) Fixed dose combination for pain relief without edema
EA201491046A1 (en) TRANSMUKOSAL'S DEVICES FOR DELIVERY OF MEDICINES FOR USE IN THE RELIEF OF CHRONIC PAIN
RU2012103957A (en) METHOD OF TREATMENT AND PREVENTION OF NASAL OBSTRUCTION IN PATIENTS WITH POLYZAL RHINOSINUSITIS
EA201990553A1 (en) APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY
CY1120970T1 (en) PHARMACEUTICAL DOSAGE FORM INCLUDING 6'-Fluoro- (N-METHYL-Ή N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3-KY-SPO , 4, B] INDOL] -4-AMINH FOR THE TREATMENT OF ALGESTIC PAIN
UA115063U (en) METHOD OF TREATMENT OF DOGS WITH PAIN SYNDROME IN PANCREATITIS
RU2010136364A (en) METHOD FOR TREATING ALCOHOLIC, NICOTINE, DRUG AND OTHER FORMS OF DEPENDENCIES